FLT #6 – Forensic Investigative Genetic Genealogy – Part II November 8, 2023 @ 1 PM ET Beyond the OMG Era: Forensic Genetic Genealogy 2011 - 2023, Expectations Versus Realities
About This Series
The Journal of Forensic Sciences (JFS) of the American Academy of Forensic Sciences (AAFS) has joined forces with Wiley to present a series of virtual educational seminars for forensic scientists.
The series will cover a range of topics important to this community highlighting the most recent methods and best practices in areas such as forensic chemistry (covering spectroscopy, microscopy, and other techniques), toxicology, trace evidence, DNA analysis, and many more.
Please Note: Previous Forensic Lab Talks participants must register below to attend this Virtual Seminar.
A Certificate of Attendance will be sent to participants who attend the FLT #6 virtual seminar live on November 8.
Identifinders International LLC
Beyond the OMG Era: Forensic Genetic Genealogy 2011 - 2023, Expectations Versus Realities
Forensic Genetic Genealogy (FGG) has been used over more than ten years to solve hundreds of cold cases, many dating back decades. Each day the media reports still another violent crime being solved, or a set of unidentified remains being identified through FGG. As more cases move forward to successful resolution, the capabilities of FGG are becoming more well characterized, tempering expectations, and mitigating the risk of over-using a technique once regarded as a miracle cure for the common cold case.
The first agencies to follow up on the initial success of FGG based on Y-STRs were those who were willing to risk time and money on a brand-new investigative technique that was obviously a game-changer, but where the probability of success had not yet been established. However, as forensic SNP testing has emerged, and the catalog of FGG cases has expanded into the hundreds, a great deal more has been learned about why certain cases succeed while others are proving intractable. Issues involving privacy versus public safety are being addressed, along with the development of policy, procedures, and credentialing that are helping FGG to interface with the present CODIS infrastructure.
This presentation will discuss case studies that offer insight into the legal, technical, and genealogical evolution of FGG, with suggestions on what the future may hold for this game-changing tool for human identification.
The Life Science business of Merck KGaA, Darmstadt Germany operates as MilliporeSigma in the U.S. and Canada.